SG162791A1 - Mucin hypersecretion inhibitors based on the structure of mans and methods of use - Google Patents

Mucin hypersecretion inhibitors based on the structure of mans and methods of use

Info

Publication number
SG162791A1
SG162791A1 SG201004172-1A SG2010041721A SG162791A1 SG 162791 A1 SG162791 A1 SG 162791A1 SG 2010041721 A SG2010041721 A SG 2010041721A SG 162791 A1 SG162791 A1 SG 162791A1
Authority
SG
Singapore
Prior art keywords
mans
methods
amino acid
acid sequence
inhibitors based
Prior art date
Application number
SG201004172-1A
Other languages
English (en)
Inventor
Indu Parikh
Original Assignee
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd filed Critical Biomarck Pharmaceuticals Ltd
Publication of SG162791A1 publication Critical patent/SG162791A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
SG201004172-1A 2005-01-20 2006-01-20 Mucin hypersecretion inhibitors based on the structure of mans and methods of use SG162791A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64529305P 2005-01-20 2005-01-20

Publications (1)

Publication Number Publication Date
SG162791A1 true SG162791A1 (en) 2010-07-29

Family

ID=36297369

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201004172-1A SG162791A1 (en) 2005-01-20 2006-01-20 Mucin hypersecretion inhibitors based on the structure of mans and methods of use

Country Status (15)

Country Link
US (5) US7524926B2 (pt)
EP (2) EP1858538B1 (pt)
JP (1) JP4926979B2 (pt)
KR (2) KR101554653B1 (pt)
CN (1) CN101146545B (pt)
AU (1) AU2006206331B2 (pt)
BR (1) BRPI0606445A2 (pt)
CA (1) CA2595406C (pt)
IL (2) IL184731A (pt)
MX (1) MX2007008744A (pt)
NZ (2) NZ577196A (pt)
RU (1) RU2423379C2 (pt)
SG (1) SG162791A1 (pt)
WO (1) WO2006078899A2 (pt)
ZA (1) ZA200706339B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
RU2423379C2 (ru) * 2005-01-20 2011-07-10 Байомарк Фармасьютикалз, Лтд. Ингибиторы гиперсекреции муцина и способы их применения
DK2053915T3 (da) * 2006-07-26 2014-06-30 Biomarck Pharmaceuticals Ltd Peptider til reducering af frigørelse af inflammatoriske mediatorer
GB0722105D0 (en) * 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
KR102191695B1 (ko) 2013-04-05 2020-12-16 바이오마크 파마슈티칼스 리미티드 전이 억제제
JP6965646B2 (ja) 2017-09-06 2021-11-10 株式会社ダイフク 搬送車、及び、搬送設備
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법
CN114302706A (zh) * 2019-06-17 2022-04-08 碧奥马尔克制药有限公司 治疗葡萄膜炎的肽及其使用方法
WO2023150791A1 (en) * 2022-02-07 2023-08-10 Biomarck Pharmaceuticals, Ltd. Peptides and methods of use thereof in treating ocular disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
AU642133B2 (en) 1988-11-18 1993-10-14 Board Of Regents Of The University Of Washington, The HDL-binding proteins
US5223421A (en) 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
JP3208139B2 (ja) 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ｉｉ▼アンタゴニスト
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
WO1993000353A1 (en) 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) * 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
WO1995027496A1 (en) 1994-04-07 1995-10-19 Proteinix Company Vasoactive intestinal polypeptide
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
WO2000050062A2 (en) 1999-02-24 2000-08-31 North Carolina State University Methods and compositions for altering mucus secretion
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001020998A1 (en) 1999-09-24 2001-03-29 Linden Technologies, Inc. Drug discovery using gene expression profiling
ATE245639T1 (de) 1999-12-03 2003-08-15 Pfizer Prod Inc Acetylenderivate zur verwendung als schmerzstillendes oder entzündungshemmendes mittel
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
EP1411967B1 (en) * 2001-06-26 2011-08-10 North Carolina State University Blocking peptide for inflammatory cell secretion
JP2004049133A (ja) * 2002-07-22 2004-02-19 Kumamoto Technology & Industry Foundation Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US7598080B2 (en) 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
US7408030B2 (en) * 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
RU2423379C2 (ru) 2005-01-20 2011-07-10 Байомарк Фармасьютикалз, Лтд. Ингибиторы гиперсекреции муцина и способы их применения
DK2053915T3 (da) 2006-07-26 2014-06-30 Biomarck Pharmaceuticals Ltd Peptider til reducering af frigørelse af inflammatoriske mediatorer

Also Published As

Publication number Publication date
IL184731A0 (en) 2007-12-03
EP1858538A2 (en) 2007-11-28
US20150274778A1 (en) 2015-10-01
BRPI0606445A2 (pt) 2009-03-10
JP4926979B2 (ja) 2012-05-09
US8293870B2 (en) 2012-10-23
US9598463B2 (en) 2017-03-21
EP1858538B1 (en) 2019-03-27
WO2006078899A2 (en) 2006-07-27
KR20140093737A (ko) 2014-07-28
EP2399599A2 (en) 2011-12-28
RU2007131424A (ru) 2009-02-27
US20100197607A1 (en) 2010-08-05
KR20070107052A (ko) 2007-11-06
KR101554653B1 (ko) 2015-10-06
US8907056B2 (en) 2014-12-09
EP2399599A3 (en) 2012-04-18
US20090275520A1 (en) 2009-11-05
WO2006078899A3 (en) 2006-12-21
JP2008528500A (ja) 2008-07-31
RU2423379C2 (ru) 2011-07-10
MX2007008744A (es) 2008-03-10
KR101445859B1 (ko) 2014-11-04
US20060205664A1 (en) 2006-09-14
CN101146545B (zh) 2012-12-26
NZ577196A (en) 2011-06-30
IL228531A0 (en) 2013-12-31
AU2006206331A1 (en) 2006-07-27
AU2006206331B2 (en) 2012-08-30
IL184731A (en) 2013-10-31
CA2595406C (en) 2017-07-11
US20130338085A1 (en) 2013-12-19
CN101146545A (zh) 2008-03-19
CA2595406A1 (en) 2006-07-27
US7524926B2 (en) 2009-04-28
AU2006206331A2 (en) 2006-07-27
NZ560412A (en) 2009-06-26
US8492518B2 (en) 2013-07-23
ZA200706339B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
SG162791A1 (en) Mucin hypersecretion inhibitors based on the structure of mans and methods of use
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
NZ749962A (en) Pegylated porcine interferon and methods of use thereof
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
MX361694B (es) Fragmentos de peptidos para inducir sintesis de proteinas de matriz extra-celular.
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
AU2007325952A8 (en) Cell-free synthesis of proteins containing unnatural amino acids
EP2251348A3 (en) Peptides and their use
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
WO2003096984A3 (en) Drug therapy for celiac sprue
ES2507094T3 (es) Proteína específica del timo
WO2005025604A3 (en) Use of hmgb and hmgb fragments to decrease specific immune response
WO2002026935A3 (en) TGF-β INHIBITORS AND METHODS
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
EP4275757A3 (en) Atf5 peptide variants and uses thereof
BRPI0707420A8 (pt) composições contendo peptídeos com aminoácidos e métodos não naturais do uso
NZ589365A (en) Peptidyl diacylglycerides
WO2006105392A3 (en) Neuron targeting peptides
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
AU5690400A (en) Novel compounds
WO2003091275A3 (en) Compositions containing anti-hiv peptides and methods of use
TW200505943A (en) Polypeptide
MX2010010177A (es) Fragmentos de beta timosina mejorada.
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.